Pyrimidine compounds and methods using the same

1. A compound according to formula (I):

or a pharmaceutically acceptable salt thereof,

wherein

Z 1 is —OR 7 or —SR 7 ;

Z 2 is —C(R 3 )═ or —N═;

each R 1 and R 2 is, independently, H, optionally substituted C 1-3 acyl, or optionally substituted C 1-3 alkyl;

R 3 and R 4 combine to form —X 1 —X 2 —X 3 —; or R 3 is H, halogen, cyano, optionally substituted C 1-6 alkyl, optionally substituted C 1-3 alkoxy, or optionally substituted amino, and R 4 is halogen, cyano, optionally substituted C 1-6 alkyl, optionally substituted C 1-3 alkoxy, optionally substituted amino, or optionally substituted C 1-6 thioalkoxy;

wherein

X 1 is —S—, —O—, —(CR 14 R 15 )—, —C(R 16 )═, —N(R 9 )—, or —N═;

X 2 is —(CR 17 R 18 ) n —, —S—, —O—, —N(R 9 )—, —C(R 19 )═, ═C(R 20 )—, or ═C(R 21 )—C(R 22 )═;

X 3 is —(CR 14 R 15 )—, —S—, —O—, —N(R 9 )—, ═N—, ═C(R 23 )—;

each R 14 and R 15 is, independently, H or optionally substituted C 1-3 alkyl, or R 14 and R 15 combine to form ═O or ═S;

each R 17 and R 18 is, independently, H or optionally substituted C 1-3 alkyl, or R 17 and R 18 combine to form ═O or ═S;

each R 16 , R 19 , R 20 , R 21 , R 22 , and R 23 is, independently, H or optionally substituted C 1-3 alkyl; and

n is 1 or 2;

R 5 is halogen, H, optionally substituted C 1-3 alkyl, optionally substituted C 1-3 alkoxy, or CN;

R 6 is halogen, H, optionally substituted C 1-3 alkyl, optionally substituted C 1-3 alkoxy, or CN;

R 7 and R 8 , together with the atoms to which each is attached, join to form an optionally substituted five membered ring comprising one or two heteroatoms selected from the group consisting of oxygen and sulfur;

R 9 is H, optionally substituted C 1-3 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl, optionally substituted C 2-9 heteroaryl, optionally substituted C 2-9 heterocyclyl, optionally substituted C 1-3 alkcycloalkyl, optionally substituted C 1-3 alkheterocyclyl, or optionally substituted C 1-3 alkaryl; and

R m is H, halogen, cyano, optionally substituted C 1-4 acyl, optionally substituted C 1-4 alkyl, or optionally substituted C 1-3 alkoxy;

wherein

when each R 5 and R 6 is chloro, Z is —OR 7 , R 7 and R 8 combine to form —CH 2 —CH 2 —, Z 2 is CR 3 , and R 3 and R 4 combine to form a group according to formula (IIa),

wherein R 9 is H or —C(O)—N(H)-(linear C 1-3 alkyl).

2. The compound of claim 1 , wherein R m is H.

3. The compound of claim 1 , wherein the compound is according to formula (Ia):

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is according to formula (Ib):

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein R 3 and R 4 combine to form —X 1 —X 2 —X 3 —, wherein —X 1 —X 2 —X 3 — comprises one nitrogen, one oxygen, or one sulfur atom; or R 3 is H, halogen, optionally substituted C 1-3 acyl, optionally substituted C 1-3 alkyl, or optionally substituted C 1-3 alkoxy, and R 4 is halogen, optionally substituted C 1-3 acyl, optionally substituted C 1-3 alkyl, optionally substituted C 1-3 alkoxy, optionally substituted amino, or optionally substituted C 1-6 thioalkyl.

6. The compounds of claim 1 , wherein R 3 and R 4 combine to form —X 1 —X 2 —X 3 —, wherein —X 1 —X 2 —X 3 — comprises one sulfur atom.

7. The compound of claim 1 , wherein R 3 and R 4 combine to form —C(R 13A )═C(R 13B )—S— group, wherein R 13A is H, and R 13B is optionally substituted C 1-3 alkyl or H.

8. The compound of claim 7 , wherein R 13B is optionally substituted C 1-3 alkyl.

9. The compound of claim 8 , wherein R 13B is —C(O)—R 13C , wherein R 13C is optionally substituted amino or optionally substituted C 1-3 alkoxy.

10. The compound of claim 1 , wherein R 3 and R 4 combine to form —C(R 13A )═C(R 13B )—S— group, wherein R 13A is H, and R 13B is —C(O)—R 13C , H, or C 1-6 aminoalkyl, wherein R 13C is optionally substituted C 1-3 alkyl, optionally substituted C 1-3 alkoxy, optionally substituted amino, or optionally substituted C 2-9 heterocyclyl.

11. The compound of claim 1 , wherein R 3 and R 4 combine to form —CH 2 CH 2 CH 2 — group.

12. The compound of claim 1 , wherein R 3 and R 4 combine to form —X 1 —X 2 —X 3 —, wherein —X 1 —X 2 —X 3 — comprises one nitrogen.

13. The compound of claim 12 , wherein R 3 and R 4 combine to form —N(R 9 )—CH═CH— group.

14. The compound of claim 1 , wherein R 3 and R 4 combine to form —X 1 —X 2 —X 3 —, wherein

X 1 is —S—, —O—, —(CR 14 R 15 )—, —C(R 16 )═, —N(R 9 )—, or —N═

X 2 is —(CR 17 R 18 ) n —, —C(R 19 )═, ═C(R 20 )—, or ═C(R 21 )—C(R 22 )═;

X 3 is —(CR 14 R 15 )—, —S—, —O—, —N(R 9 )—, ═N—, or ═C(R 23 )—.

15. The compound of claim 1 , wherein R 7 and R 8 form a group —Y 1 —Y 2 —, wherein:

Y 1 is —(CR 26 R 27 ) m —; and

Y 2 is —(CR 26 R 27 )—; wherein

each R 26 and R 27 is, independently, H or optionally substituted C 1-3 alkyl;

m is 1.

16. The compound of claim 1 , wherein Z 1 and R 8 combine to form —Z 3 —Y 1 —Y 2 —, wherein

Z 3 is —O— or —S—;

Y 1 is —(CR 26 R 27 ) m — or —C(R 20 )═; and

Y 2 is —O—, —S—, —(CR 26 R 27 )—, or ═C(R 20 )—;

wherein

each R 20 is, independently, H or optionally substituted C 1-3 alkyl; and

each R 26 and R 27 is, independently, H or optionally substituted C 1-3 alkyl, or R 26 and R 27 combine to form ═O or ═S;

m is 1 or 2.

17. A compound:

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 17 having the formula:

or a pharmaceutically acceptable salt thereof.

19. A compound according to the structure:

or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more of pharmaceutically acceptable carriers or excipients.

21. A method of treating a disorder in a mammal caused by the action of heat shock protein 90 (Hsp90), said method comprising administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to said mammal, wherein said disorder is Alzheimer's disease, Huntington's disease, progressive supranuclear palsy, Parkinson's disease, Pick's disease, corticobasal degeneration, chronic traumatic encephalopathy, traumatic brain injury, or frontotemporal dementia.

22. The method of claim 21 , wherein said disorder is Alzheimer's disease.

23. A method of treating a disorder in a mammal caused by the action of heat shock protein 90 (Hsp90), said method comprising administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to said mammal, wherein said disorder is cancer.

24. A method of treating an infectious disease in a mammal, said method comprising administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to said mammal.

25. The method of claim 24 , wherein said infectious disease is a viral, fungal, or bacterial infection.

26. The method of claim 25 , wherein said infectious disease is an infection by a virus of a family selected from the group consisting of Herpesviridae, Polyomaviridae, Poxviridae, Reoviridae, Birnaviridae, Picornaviridae, Flaviviridae, Arenaviridae, Hepeviridae, Rhabdoviridae, Paramoxyviridae, Bunyaviridae, Orthomoxyviridae, Filoviridae, Retroviridae, and Hepadnaviridae.

27. A method of treating a disorder in a mammal caused by the action of heat shock protein 90 (Hsp90), said method comprising administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to said mammal, wherein said disorder is an inflammatory or autoimmune disease.

28. The method of claim 27 , wherein said inflammatory or autoimmune disease is rheumatoid arthritis, systemic lupus erythermatosus, or asthma.

29. A method of treating a disorder in a mammal caused by the action of heat shock protein 90 (Hsp90), said method comprising administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to said mammal, wherein said disorder is a cardiovascular disease.

30. The method of claim 29 , wherein said cardiovascular disease is atherosclerosis.

31. A method of treating a disorder in a mammal caused by the action of heat shock protein 90 (Hsp90), said method comprising administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to said mammal, wherein said disorder is an allergy.

32. A method of inhibiting Hsp90, said method comprising contacting a cell with the compound of claim 1 or a pharmaceutically acceptable salt thereof.

33. A kit comprising:

(i) the pharmaceutical composition of claim 20 ; and

(ii) instructions for use of the pharmaceutical compositions of (i) to treat a disorder in a mammal caused by the action of Hsp90.